I am assigning Pfizer (NYSE:PFE) a positive risk/reward rating based on the company’s attractive valuation and its successful transformation into a pure growth-oriented biopharmaceutical company. Pfizer’s impressive COVID vaccine execution was the culmination of a multi-year strategic business transformation. The company has successfully transitioned from a mature pharmaceutical company into an innovative, growth-focused company leveraging the cutting edge of biotechnology. Pfizer’s ability to respond at scale and speed to the COVID crisis highlights the asymmetric growth opportunities available to it in the biopharmaceutical industry. The opportunity set is further amplified by the incredible pace of advancement in biotechnology which is enabling innovation at speed and scale like never before.
Continue reading this report with a stoxdox membership.